Participated · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Participated · Series C · Aug 2026

Epicrispr Biotechnologies develops programmable epigenetic medicines designed to durably regulate gene expression without altering DNA sequence, leveraging its proprietary GEMS platform. Its lead program, EPI-321, is an investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD) delivered in a single AAV vector intended to target muscle following intravenous administration. EPI-321 is in a Phase 1/2 trial with enrollment completed and interim results showing statistically significant increases in whole-body lean muscle volume, favorable biomarker changes consistent with DUX4 suppression, and a manageable safety profile. The company is advancing additional gene-modulating programs across multiple therapeutic areas and plans to expand its manufacturing capabilities. Epicrispr is based in San Francisco and is positioning to move EPI-321 into pivotal studies as it develops its next-generation programmable epigenetic medicines.

Participated · Series B · Aug 2026

Expedition Therapeutics is developing next-generation oral small molecule therapies targeting inflammatory and respiratory diseases, with its lead program EXPD-101, a once-daily DPP1 inhibitor, currently in a global Phase 2 trial for COPD. The company reported that EXPD-101 was well tolerated in Phase 1 with no dose-limiting toxicities and showed dose-proportional pharmacokinetics supporting once-daily dosing. The first patient has been dosed in the Phase 2 COPD study, marking the company’s transition into mid-stage clinical development. Expedition combines translational expertise and clinical development experience with a platform for in-licensing global innovation. The recent $115 million Series B financing led by General Atlantic is intended to fund EXPD-101 through Phase 2, expand the company’s pipeline of therapies for inflammatory diseases, and further its research discovery efforts. Expedition is based in San Francisco and has announced board expansion tied to the financing.

Participated · Series B · Aug 2026

QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.